<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04635423</url>
  </required_header>
  <id_info>
    <org_study_id>V503-064</org_study_id>
    <secondary_id>2020-001047-67</secondary_id>
    <secondary_id>V503-064</secondary_id>
    <secondary_id>jRCT2031200217</secondary_id>
    <nct_id>NCT04635423</nct_id>
  </id_info>
  <brief_title>Efficacy, Immunogenicity, and Safety Study of the 9vHPV Vaccine in Japanese Males (V503-064)</brief_title>
  <official_title>A Phase 3, Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9vHPV Vaccine in Japanese Males, 16 to 26 Years of Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this phase 3, double-blind, placebo-controlled clinical study are to evaluate&#xD;
      the efficacy of V503 (9-valent human papillomavirus [9vHPV] vaccine) in preventing&#xD;
      HPV-related anogenital persistent infection, and to evaluate the safety/tolerability of V503,&#xD;
      in Japanese males who are 16 to 26 years of age. It is hypothesized that administration of a&#xD;
      3-dose regimen of V503 reduces the combined incidence of HPV 6/11/16/18-related anogenital&#xD;
      persistent infection, as well as the combined incidence of HPV 31/33/45/52/58-related&#xD;
      anogenital persistent infection, compared with placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2020</start_date>
  <completion_date type="Anticipated">January 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined incidence of HPV 6/11/16/18-related anogenital persistent infection</measure>
    <time_frame>Up to 42 months</time_frame>
    <description>This endpoint is defined to have occurred in a participant 1) who is polymerase chain reaction (PCR) positive to HPV 6, 11, 16 or 18 in 2 consecutive anogenital or biopsy samples from at least 2 consecutive visits 6 months (+/- 1-month visit window) or longer apart, or 2) who has a pathology diagnosis of condyloma, penile/perineal/perianal intraepithelial neoplasia, or penile, perineal or perianal cancer and PCR detection of HPV 6, 11, 16, or 18 in an adjacent section and PCR positive for the same HPV type at a separate adjacent visit. The incidence of this endpoint is assessed in each treatment arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with solicited injection-site adverse events (AEs)</measure>
    <time_frame>Up to 5 days after injection</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with ≥1 systemic AE</measure>
    <time_frame>Up to 15 days after injection</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with ≥1 serious adverse events (SAEs)</measure>
    <time_frame>Up to 6 months postdose 3 (up to 12 months)</time_frame>
    <description>An SAE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention, that results in death, is life-threatening, requires hospitalization or prolongs existing hospitalization, results in persistent/significant disability/incapacity, is a congenital birth defect, or is an other important medical event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined incidence of HPV 31/33/45/52/58-related anogenital persistent infection</measure>
    <time_frame>Up to 42 months</time_frame>
    <description>This endpoint is defined to have occurred in a participant 1) who is PCR positive to HPV 31, 33, 45, 52, or 58 in 2 consecutive anogenital or biopsy samples from at least 2 consecutive visits 6 months (+/- 1-month visit window) or longer apart, or 2) who has a pathology diagnosis of condyloma, penile/perineal/perianal intraepithelial neoplasia, or penile, perineal or perianal cancer and PCR detection of HPV 31, 33, 45, 52, or 58 in an adjacent section and PCR positive for the same HPV type at a separate adjacent visit. The incidence of this endpoint is assessed in each treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titers (GMTs) to HPV 6/11/16/18/31/33/45/52/58</measure>
    <time_frame>Month 7</time_frame>
    <description>Serum antibody titers are measured with a competitive Luminex immunoassay (cLIA).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1050</enrollment>
  <condition>Warts, Genital</condition>
  <condition>Neoplasms, Anal</condition>
  <arm_group>
    <arm_group_label>V503</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive an intramuscular (IM) injection of V503 at Day 1, Month 2, and Month 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive an IM injection of placebo at Day 1, Month 2, and Month 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V503</intervention_name>
    <description>9-valent vaccine, HPV 6/11/16/18/31/33/45/52/58, L1 virus-like particle (VLP) 30/40/60/40/20/20/20/20/20 mcg per dose.</description>
    <arm_group_label>V503</arm_group_label>
    <other_name>9vHPV vaccine</other_name>
    <other_name>SILGARD®9</other_name>
    <other_name>GARDASIL™9</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% sodium chloride (NaCL)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is a Japanese male 16 to 26 years of age&#xD;
&#xD;
          -  Has no more than 5 lifetime sexual partners&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a history of known prior vaccination with an HPV vaccine or plans to receive one&#xD;
             outside the study&#xD;
&#xD;
          -  Has a history of external genital warts&#xD;
&#xD;
          -  Has a history of severe allergic reaction that required medical intervention&#xD;
&#xD;
          -  Has received immune globulin or blood-derived products in the past 3 months or plan to&#xD;
             receive any before Month 7 of the study&#xD;
&#xD;
          -  Has a history of splenectomy, is currently immunocompromised, or has been diagnosed&#xD;
             with immunodeficiency, human immunodeficiency virus (HIV), lymphoma, leukemia,&#xD;
             systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis,&#xD;
             inflammatory bowel disease, or other autoimmune condition&#xD;
&#xD;
          -  Has received immunosuppressive therapy in the past year, excluding inhaled, nasal, or&#xD;
             topical corticosteroids and certain regimens of systemic corticosteroids&#xD;
&#xD;
          -  Has a known thrombocytopenia or coagulation disorder that would contraindicate&#xD;
             intramuscular injections&#xD;
&#xD;
          -  Has ongoing alcohol or drug abuse within the past 12 months&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Umeyama Clinic ( Site 6406)</name>
      <address>
        <city>Takasaki</city>
        <state>Gunma</state>
        <zip>370-0826</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-27-328-5500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Association of Healthcare Corporation Koukankai Koukan Clinic ( Site 6424)</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>210-0852</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-44-366-8900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocean Clinic ( Site 6407)</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>231-8331</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-45-641-0777</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kanno Clinic ( Site 6402)</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <zip>590-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-72-258-0666</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>P-One Clinic, Keikokai Medical Corp. ( Site 6419)</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>192-0071</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-42-625-5216</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Iwasa Clinic ( Site 6411)</name>
      <address>
        <city>Osaka</city>
        <zip>542-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-6-6213-2841</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nomura Clinic Namba ( Site 6405)</name>
      <address>
        <city>Osaka</city>
        <zip>542-0076</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Seiwakai Hayakawa Clinic ( Site 6409)</name>
      <address>
        <city>Osaka</city>
        <zip>542-0086</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yamanaka Clinic ( Site 6410)</name>
      <address>
        <city>Osaka</city>
        <zip>553-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-6-6343-8700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Doujin Memorial Medical Foundation, Meiwa Hospital ( Site 6404)</name>
      <address>
        <city>Tokyo</city>
        <zip>101-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3251-0263</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yuge Clinic ( Site 6421)</name>
      <address>
        <city>Tokyo</city>
        <zip>103-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3666-3979</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taisei Clinic ( Site 6403)</name>
      <address>
        <city>Tokyo</city>
        <zip>107-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-6426-5933</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mildix Skin Clinic ( Site 6423)</name>
      <address>
        <city>Tokyo</city>
        <zip>120-0034</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-50-3734-0692</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sugisawa Dermatology Clinic ( Site 6422)</name>
      <address>
        <city>Tokyo</city>
        <zip>125-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3826-7061</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Sanshikai Toru Clinic ( Site 6401)</name>
      <address>
        <city>Tokyo</city>
        <zip>132-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-5664-8020</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Mori to Umi Tokyo Tokyo Kamata Hospital ( Site 6418)</name>
      <address>
        <city>Tokyo</city>
        <zip>144-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3733-0525</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seiyukai Medical Corporation Itoh Skin Clinic ( Site 6416)</name>
      <address>
        <city>Tokyo</city>
        <zip>154-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3422-0663</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Naoko Dermatology Clinic ( Site 6417)</name>
      <address>
        <city>Tokyo</city>
        <zip>158-0097</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-6805-7484</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Iseikai My City Clinic ( Site 6414)</name>
      <address>
        <city>Tokyo</city>
        <zip>160-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3354-3411</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shinjuku Higashiguchi Clinic ( Site 6415)</name>
      <address>
        <city>Tokyo</city>
        <zip>160-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-5366-3389</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ogikuboekimae Clinic ( Site 6413)</name>
      <address>
        <city>Tokyo</city>
        <zip>167-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3220-9622</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kusunoki Clinic ( Site 6412)</name>
      <address>
        <city>Tokyo</city>
        <zip>175-0092</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3939-0096</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Condylomata Acuminata</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

